الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
AML is a haematological malignancy characterized by a wide range of mutated genes and a wide genomic architecture composed of preleukemic and leukemic clones that unfold progressively over time allowing us to more prominently understand the different prognostic and predictive features aiming for a more effective therapeutic approach.
AML patients usually present with clinical signs and symptoms related to bone marrow infiltration by leukemic blasts resulting in disruption of normal hematopoiesis with manifestations of infections, anemia, and thrombocytopenia.
AML is defined as greater than or equal to 20% blasts in the peripheral blood or bone marrow, except in patients with the following cytogenetic abnormalities who are classified as having AML irrespective of blast percentage: t(8;21) (q22;q22), inv(16)(p13q22), t(16;16)(p13;q22), and t(15;17)(q22;q12).
While 7+3 remains the standard treatment for a large subgroup of patients, recent drug approvals as previously mentioned have demonstrated improved survival with add-on and alternative agents in defined patient populations.
Protein arginine methylation is a posttranslational modification that is activated by the PRMT family of which PRMT1 is the most predominant isoform in mammalian cells and acts in several pathways including transcription regulation, repair of DNA, programmed cell death, and cell proliferation.
Our study aimed to evaluate the impact of PRMT1 gene expression levels on several factors included in the diagnosis of AML and more importantly its impact on response to standard induction chemotherapy in Egyptian adult AML patients aged from 18-60 years.
The presented study was conducted on 40 newly diagnosed AML patients in Alexandria Main University Hospital, Alexandria, Egypt. All submitted patients were diagnosed by performing bone marrow aspiration and immunophenotyping, as well as undergoing routine chemical testing, molecular tests (FLT3 gene mutation, NPM1 gene mutation) and conventional karyotyping. Bone marrow samples were also tested for PRMT1 gene expression level.
Patients received induction chemotherapy with the standard [7+3] protocol.
- Cytarabine 100 mg/m2 continuous infusion from day 1 to day 7
- Daunorubicin 45 mg/m2 on days 1, 3 and 5.
The results of the study revealed that:
1- There was no statistical significance in PRMT1 expression levels in newly diagnosed AML patients as compared to healthy controls.
2- PRMT1 expression levels were significantly higher in patients who suffered an unfavourable response to induction treatment than those who achieved complete remission.
3- There was no statistically significant difference in patients’ presenting symptoms, treatment related toxicities, relapse free survival or overall survival as regards to PRMT1 expression level.